Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials | Scientific Reports
Multiple myeloma current treatment algorithms | Blood Cancer Journal
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US | SpringerLink
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation) for patients with multiple myeloma awaiting autologous haematopoietic stem cell transplantation? Protocol for the PREeMPT study | BMJ Open
Hull University Teaching Hospitals and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway Mu
Treatment of relapsed and refractory multiple myeloma | Haematologica
Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma - eBioMedicine
DVd - Darzalex + Velcade + dex - Myeloma | ChemoExperts
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective - ScienceDirect
Cancers | Free Full-Text | Recent Advances in the Treatment of Patients with Multiple Myeloma
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion. - Abstract - Europe PMC
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
VAD and similar alternate regimens | Download Table
Approved for use in:
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study - ScienceDirect
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
SYNOPSIS
DVd - Darzalex + Velcade + dex - Myeloma | ChemoExperts
3630-Multiple myeloma DVd (daratumumab bortezomib dexamethasone) overview | eviQ
DVdSC (weekly cycles1-8) Bortezomib-Daratumumab-Dexamethasone Ver1
Overall survival in a cohort of multiple myeloma patients treated with... | Download Scientific Diagram
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients | British Journal of Cancer
